Research Article
Plasma IL-6/IL-10 Ratio and IL-8, LDH, and HBDH Level Predict the Severity and the Risk of Death in AIDS Patients with Pneumocystis Pneumonia
Table 1
Clinical characteristics and baseline demographics of AIDS PCP patients.
| | Characteristics | |
| | Gender (M/F) | 32 (32/0) | | Age, years | 40.72 ± 12.03 | | The most recent CD4 cell count | 87.14 ± 14.46 | | HIV-RNA, copies/mL | | | 200 mmHg, | 23534.74 ± 23616.33 | | ≤200 mmHg, | 263789.65 ± 208749.16 | | PaO2/FiO2 before therapy | 208.96 ± 90.03 | | 200 mmHg, | 268.92 ± 44.26 | | ≤200 mmHg, | 109.00 ± 44.94 | | Mode of transmission | | | Heterosexual transmission | 19 (59.38%) | | Homosexual transmission | 12 (37.50%) | | Bisexual transmission | 1 (3.12%) | | Underline disease | | | Candidiasis (oral/pulmonary) | 15 (10/5) | | Syphilis (neurosyphilis) | 6 (1) | | Aspergillosis (esophagus/pulmonary) | 6 (5/1) | | Tuberculosis (intestinal/pulmonary) | 2 (1/1) | | Tinea cruris | 1 | | Herpes zoster | 1 | | CMV retinitis | 1 | | Seborrheic dermatitis | 1 | | Hematology disorders | 1 | | Hepatic insufficiency | 1 | | Psychonosema | 1 | | Nutritional deficiencies | 1 | | Hypokalemia | 1 | | Pneumothorax | 1 | | COPD | 1 | | Hypertension | 1 | | Treatment | | | SMZ-TMP prophylaxis | 0 (0%) | | HARRT before PCP | 3 (9.40%) | | Anti-PCP therapy | 32 (100%) | | SMZ-TMP | 32 (100%) | | Clindamycin | 32 (100%) | | Caspofungin | 11 (34.38%) | | Antibiotic therapy | 29 (90.63%) | | Antifungal therapy | 29 (90.63%) | | Glucocorticoid therapy | 30 (93.75%) | | Mechanical ventilation | 2 (6.25%) | | Clinical outcome | | | Survivor | 25 (78.12%) | | Nonsurvivor | 7 (21.88%) |
|
|
